Harbour Antibodies BV, founded in 2006, specializes in the development of next-generation transgenic mouse strains for the discovery of human monoclonal antibodies. Utilizing technology from Professor Frank Grosveld's laboratory at Erasmus MC Rotterdam, the company has engineered mice to produce high-affinity human antibodies. Harbour Antibodies offers two types of transgenic mice: those generating tetrameric antibodies with two heavy and two light immunoglobulin chains (H2L2), and those generating heavy chain-only antibodies (HCAbs) with no light chains. These mice are essential for developing therapeutic antibodies targeting diseases with unmet medical needs. The company primarily serves biopharmaceutical firms and research institutions, operating in the biotechnology and pharmaceutical markets. Harbour Antibodies generates revenue through the sale and licensing of its transgenic mouse models and related technologies.

Keywords: transgenic mice, human antibodies, monoclonal antibodies, therapeutic development, biotechnology, biopharmaceutical, immunoglobulin, H2L2, HCAbs, high-affinity.